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Abstract Some of the numerous functions of the growth 
suppressor protein p53 are regulated by its interaction with viral 
and cellular proteins. C-terminal sequences of p53 are implicated 
in binding to the regulatory ß-subunit of protein kinase CK2. 
Using a p53-specific DNA binding element we found that the ß-
subunit of CK2 inhibited the DNA binding of p53 whereas the oc-
subunit had no influence. The CK2 holoenzyme consisting of two 
a- and two ß-subunits led to a supershift in DNA binding of p53 
similar to the p53-specific monoclonal antibody PAb421 as well 
as the C-terminus of p53. Thus, our results showed an individual 
role of the free ß-subunit of CK2 on the DNA binding activity of 
p53. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The growth suppressor protein p53 plays an important role 
governing the integrity of the human genome. Upon DNA 
damage it can induce growth arrest, DNA repair or apoptosis 
(for review see [1]). Some of the p53 functions are performed 
by sequence-specific DNA binding [2], by interaction with dif-
ferent transcription factors such as TBP (TATA-box binding 
protein) [3], TAFII40 and TAFII60 [4], TAFII31 [5], SP1 [6] 
and E2F [7]. So far a number of p53-responsive elements has 
been identified some of which are up-regulated upon DNA 
damage-induced accumulation of p53 and which appear to 
be involved in cell cycle arrest such as p21W A i l /C I 1 ' 1 [8], 
some in DNA replication and DNA repair such as PCNA or 
GADD45 [9,10], some are involved in apoptosis such as bcl-2 
and baX 1 [11] or in a self-regulating loop such as mdm2 [12]. 
The p53 protein is phosphorylated by several protein kin-
ases at multiple sites which are clustered in the N-terminus 
and in the C-terminus (for review see [13]). The polypeptide 
chain of p53 can be divided into several functional domains: 
the N-terminus which seems to be involved in transcriptional 
activation [14], the central core domain which is responsible 
for the sequence-specific DNA binding activity [15] and a C-
terminal region. The C-terminus of p53 harbors the oligome-
rization domain [16], nuclear localization signals [17], the 
binding sites for the fission yeast tmsl protein [18], for 
DnaK [19], TBP, XPB and RPA [20], the regulatory ß-subunit 
of protein kinase CK2 [21] and protein kinase p34cdc2 (Wag-
ner et al., submitted). The carboxy-terminal region is able to 
bind non-specifically to DNA [22] and to influence the specific 
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binding of p53 to DNA. Specific DNA binding of p53 is 
strongly activated (i) by binding of monoclonal antibody 
PAb421 to its C-terminal epitope [19], (ii) when a C-terminal 
30 amino acid long sequence is deleted or (iii) when human 
p53 is phosphorylated by protein kinase CK2 at residue 392 
[19]. Recent results have shown that O-glycosylation in the C-
terminus also regulates DNA binding activity of p53 [23]. C-
terminal regions of the p53 polypeptide are also involved in 
recognizing insertion-deletion mismatches [24] and in DNA 
reannealing activity [25]. 
We have recently defined a new functional domain in the C-
terminus where the fission yeast tmsl protein [18], the regu-
latory ß-subunit of protein kinase CK2 [21] and the protein 
kinase p34cdc2 (Wagner et al., submitted) bind. Furthermore, 
we could show that binding of the C-terminus of p53 to the 
regulatory ß-subunit of protein kinase CK2 regulates CK2 
phosphotransferase activity [26]. CK2 is an ubiquitous ser-
ine/threonine kinase found in both the cytoplasm and the 
nucleus [27] of eukaryotic cells. It is a highly conserved 
Ca2+- and nucleotide-independent tetrameric enzyme which 
phosphorylates a broad spectrum of substrates including nu-
clear oncoproteins, transcription factors and DNA binding 
proteins [28]. In the present paper we have analyzed whether 
the regulatory ß-subunit, the catalytic oc-subunit of CK2 or 
the CK2 holoenzyme might influence the DNA binding of 
p53. We found that the CK2 holoenzyme led to a supershift 
of the p53/DNA complexes. The regulatory ß-subunit reduced 
the DNA binding activity of p53 whereas the α-subunit of 
CK2 did not influence DNA binding of p53 at all. 
2. Materials and methods 
2.1. Cell extracts 
Sf9 cells were grown in Sf900 medium supplemented with 10% fetal 
calf serum (FCS) at 27°C. Cells were infected with recombinant ba-
culovirus pAchup53wt (kindly provided by M. Hoever, Freiburg, Ger-
many) or wild-type baculovirus Autographa californica. Three days 
after infection cells were harvested, washed with PBS (phosphate-buf-
fered saline) and resuspended in lysis-buffer (10 mM Hepes, pH 7.9, 
400 mM NaCl, 20% (v/v) glycerol, 1 mM EDTA). After three cycles 
of freezing and thawing cells were centrifuged (4°C, 10 min 13000Xg). 
For each cell extract the protein concentration was determined and 
equal amounts of protein were used for further experiments. 
2.2. Labeling of cells 
Three days after infection with pAchup53wt Sf9 cells were labeled 
with [35S]methionine for 10 h. Cells were washed with PBS, resus-
pended in extraction buffer (100 mM Tris-HCl, pH 9, 100 mM 
NaCl, 0.5% NP-40) and incubated at 0°C for 1 h. After centrifugation 
the cell extract was pre-incubated 3 times with S. aureus. The super-
natant was incubated with the p53-specific monoclonal antibody 
PAbl620 [29]. Immunoprecipitates were washed 2 times in washing 
buffer C (50 mM Tris-HCl, pH 8, 500 mM LiCl, 1 mM dithiothreitol, 
1 mM Na3-EDTA, 1% (v/v) Trasylol), 3 times in NET buffer (50 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM Na3-EDTA, 5% sucrose) 
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containing 1% NP-40 and 2 times in 50 mM NH4HCO3. Proteins 
were eluted from the S. aureus complexes with sample buffer (65 
mM Tris-HCl, pH 6.8, 5% (v/v) ß-mercaptoethanol, 2% (w/v) sodium 
dodecyl sulphate, 10% (v/v) glycerol, 0.01% (w/v) bromophenol blue). 
The samples were analyzed on a 10% SDS-polyacrylamide gel and 
visualized by fluorography as described earlier [30]. 
2.3. Purification of proteins 
Recombinant CK2 holoenzyme (kind gift from Y. Shi, New York, 
USA) [31], the a- and ß-subunits of CK2 (kindly provided by O.-G. 
Issinger, Odense, DK) [32] were expressed in E. coli (BL21 (DE3)). 
The bacterial pellet was lysed and after incubation on ice for 30 min, 
the lysate was sonicated 2 times and centrifuged (lOOOOXg, step 1) 
The pellet was resuspended in buffer PI 500 (20 mM Tris-HCl, pH 8, 
7 mM ß-mercaptoethanol, 1 mM phenylmethyl sulfonylchloride 
(PMSF) and 1.5 M NaCl). Proteins were extracted overnight, pooled 
with the supernatant from the first step, and dialysed against buffer 
P300 (20 mM Tris-HCl, pH 8, 7 mM ß-mercaptoethanol, 1 mM 
PMSF and 300 mM NaCl). The lysate was loaded onto a PI 1 column 
pre-equilibrated with buffer P300 and eluted with a linear gradient 
from 0.3-1.5 mM NaCl. Fractions containing active holoenzyme, a-
or ß-subunit were dialysed against P300 buffer, concentrated and 
loaded onto a Superose-6 column (Pharmacia, Freiburg, Germany). 
After gel filtration the peak fractions were collected. 
2.4. DNA binding 
The DNA consensus sequence 5'-CCGGGCATGTCCGGGCA-
TGTCCGGGCATGT-3' [33] (kindly provided by M. Mundt, Frei-
burg, Germany) was labeled in the presence of [a-32P]dCTP. A bind-
ing reaction (20 μΐ vol.) contained binding buffer (final concentration: 
50 mM Tris-HCl, pH 8, 4% (v/v) glycerol, 5 mM dithiothreitol, 1 mM 
MgCl2 and 0.05% (v/v) Triton X-100), labeled DNA (45 ng), 12.5 μg 
tRNA and 1.25 μg poly[d(AT)] as competitors, 100 ng PAb421 when 
indicated and 9 μg of p53 containing cell extract or of control cell 
extract. We added the α-subunit or the ß-subunit or the holoenzyme 
of CK2 to p53 up to a final molar ratio of 1:1. Proteins were pre-
mixed (antibody was added at last) before DNA was added. After 30 
min at room temperature the mixture was analyzed on a 4% non-
denaturing polyacrylamide gel and visualized by autoradiography. 
3. Results 
The wild-type p53 protein binds DNA in a sequence-specific 
manner. El-Deiry et al. [34] defined a consensus p53 binding 
site consisting of two copies of the 10 bp element 5'-PuPuPu-
C(A/T)(T/A)GPyPyPy-3'. Although the central region of p53 
is clearly implicated in direct contact to DNA a contribution 
of C-terminal amino acids to its non-specific DNA binding as 
well as to its specific DNA binding is well established [15,33]. 
We have recently defined a new functional domain on the 
polypeptide chain of p53 spanning from amino acids 287-
340 where several cellular proteins bind [18,21]. Among these 
proteins that bind to this C-terminal domain is the regulatory 
ß-subunit of protein kinase CK2 [21,35]. Now, we wanted to 
analyze the influence of the CK2 holoenzyme and its individ-
ual subunits on the DNA binding activity of p53. In accord-
ance with several other studies [23,36] binding assays were 
performed using insect cells infected with a recombinant p53 
expressing baculovirus pAchup53wt. As control we used wild-
type baculovirus (Autographa californica) infected cells in or-
der to exclude unspecific DNA binding reactions. 
In order to show the protein expression in insect cells, Sf9 
cells were infected with baculovirus pAchup53wt or wild-type 
baculovirus. Three days after infection cells were labeled with 
[35S]methionine. After lysis cell extracts were immunoprecipi-
tated with antibody PAbl620 and S. aureus. The washed im-
munoprecipitates were separated on an SDS-polyacrylamide 
gel (Fig. 1A). As shown in lane 4, insect cells infected with 
pAchup53wt expressed p53, while this protein is absent in 
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insect cells infected with wild-type baculovirus A. californica 
(lane 2) and in control immunoprecipitations (lanes 1 and 3). 
The protein kinase CK2 holoenzyme consists of two cata-
lytic oe-subunits and two regulatory ß-subunits. The function-
ally active holoenzyme and the a- and ß-subunit of CK2 were 
expressed in bacteria and purified as described in Section 2. 
Purified proteins were analyzed on an SDS-polyacrylamide 
gel. Fig. 1B-D shows a Coomassie blue stain of the a-subunit, 
ß-subunit and the CK2 holoenzyme, respectively, on the SDS-
polyacrylamide gel. 
Having shown the specificity and purity of the proteins we 
now started to analyze the DNA binding of p53 in the pres-
ence or absence of protein kinase CK2. For band shift assays 
we used a DNA consensus sequence for p53 described by El-
Deiry et al. [34]. 32P-labeled oligonucleotides were analyzed on 
a polyacrylamide gel in the presence or absence of p53 and 
purified protein kinase CK2 holoenzyme. Lane 1 of Fig. 2 
shows the migration of the 32P-labeled oligonucleotide. Addi-
tion of a p53 containing cell extract from Sf9 cells led to a 
band shift (lane 9). In agreement with published results addi-
tion of the p53-specific monoclonal antibody PAb421 resulted 
in a supershift (lane 8) [19]. In the absence of PAb421 but in 
the presence of the CK2 holoenzyme p53-DNA complexes 
were also supershifted (lane 11). The supershift is in the 
same range which was obtained with PAb421 although not 
identical. Addition of PAb421 to p53 and CK2 holoenzyme 
resulted in a stronger DNA binding with no additional shift 
(lane 10). Thus, the CK2 holoenzyme seems to have a very 
similar effect on p53 as monoclonal antibody PAb421. Con-
trol experiments showed that the holoenzyme did not bind to 
the p53 consensus sequence (lane 2) nor did the p53-specific 
antibody PAb421 interfere with CK2 (lane 3). The incubation 
of the control cell extract with CK2 holoenzyme and DNA 
did not differ from control cell extract alone with DNA (lane 
7 and lane 5, respectively). Lane 4 shows the control cell 
extract incubated with antibody PAb421 and DNA and lane 
6 shows the control cell extract incubated with antibody 
PAb421 and CK2 holoenzyme. Some very weak bands repre-
sent the unspecific DNA binding of the cellular proteins and 
are different from those obtained with p53-containing cell ex-
tract. 
Next, we wanted to analyze the effect of the CK2 a-subunit 
on the DNA binding properties of p53. Therefore, we re-
peated the experiments described above but instead of the 
holoenzyme we added only the α-subunit of CK2. Lane 1 of 
Fig. 3 shows the migration of the labeled DNA. As shown in 
lane 7 p53 alone binds to DNA, and addition of PAb421 to 
p53 led to a supershift of the p53-DNA complexes (lane 8). 
The presence of the α-subunit of CK2 did not change the 
mobility of the bands on the gel regardless of whether 
PAb421 was present (lanes 10 and 9). Thus, we conclude 
that the α-subunit of CK2 does not influence the DNA bind-
ing activity of p53, which is in agreement with the observation 
that the α-subunit of CK2 does not bind to p53 [21,35]. The 
a-subunit of CK2 does also not bind to the consensus DNA-
sequence (lane 2). Lane 3 shows the control cell extract incu-
bated with DNA. Addition of PAb421 to the control cell 
extract and DNA (lane 4) or to control cell extract, DNA 
and CK2 α-subunit (lane 5) showed no specific DNA binding. 
Lane 6 shows the control cell extract with DNA, a-subunit 
and PAb421. 
Next, we repeated the experiment described above, but in-
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Fig. 1. A: Expression of human p53 in insect cells infected with wild-type baculovirus Autographa californica or with recombinant pAchup53wt 
baculovirus. 72 h after infection insect cells labeled with [35S]methionine were extracted and the cell extract incubated with S. aureus alone (—) 
or with the p53-specific monoclonal antibody PAM620 (+). Immunoprecipitates were analyzed on a 10% SDS-polyacrylamide gel. Protein 
bands were visualized by autoradiography. Lanes 2 and 4 show the immunoprecipitates with antibody PAM620 and S. aureus. Lanes 1 and 3 
show the control precipitate with S. aureus alone. B-D: Bacterially expressed ce-subunit, ß-subunit and holoenzyme of protein kinase CK2. The 
ct-subunit, ß-subunit as well as the bicistronic construct of the holoenzyme of CK2 were expressed in bacteria. Purified proteins were analyzed 
on a 10% SDS-polyacrylamide gel. Gels were stained with Coomassie blue. Molecular mass markers are ovotransferrin 78000 Da (78), bovine 
serum albumin 66000 Da (66), ovalbumin 43000 Da (43), carboanhydrase 30000 Da (30), myoglobin 17000 (17) and cytochrome c 12000 Da 
(12). 
stead of adding the α-subunit of CK2 we added the ß-subunit. 
For these experiments we used cell extracts with ß-subunit of 
CK2 expressed in insect cells or alternatively purified bacte-
rially expressed ß-subunit of CK2. Both experiments led to the 
same results. As shown in Fig. 4 lane 2, addition of p53 to the 
labeled oligonucleotide (the migration of the DNA is shown 
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shows the endlabeled oligonucleotide in the absence of p53. 
Thus at a molar ratio of 4:1 the ß-subunit of CK2 is already a 
potent inhibitor of the DNA binding activity of p53. 
4. Discussion 
Fig. 2. DNA binding activity of p53 in the presence of the CK2 
holoenzyme. The 32P-labeled oligonucleotide containing the p53 con-
sensus sequence was incubated under DNA binding conditions with 
cell extracts (p53 or control, respectively) in the absence (lanes 1, 4, 
5, 8, 9) or presence (lanes 2, 3, 6, 7, 10, 11) of CK2 protein. In ad-
dition lanes 3, 4, 6, 8 and 10 contain monoclonal antibody PAb421. 
After an incubation time of 30 min the probes were analyzed on a 
4% polyacrylamide gel followed by autoradiography of the gel. 
Lane 1: DNA. Lane 2: DNA with CK2. Lane 3: DNA with CK2 
and PAb421. Lane 4: Control cell extract with DNA and PAb421. 
Lane 5: Control cell extract with DNA. Lane 6: Control cell extract 
with DNA, CK2 and PAb421. Lane 7: Control cell extract with 
DNA and CK2. Lane 8: p53 cell extract with DNA and PAb421. 
Lane 9: p53 cell extract with DNA. Lane 10: p53 cell extract with 
DNA, CK2 and PAb421. Lane 11: p53 cell extract with DNA and 
CK2. 
The polypeptide chain of p53 has three major functional 
domains. The N-terminus is involved in transcriptional acti-
vation. The central core domain confers a sequence-specific 
DNA binding property on wild-type p53. The C-terminus of 
p53 is involved in various protein-protein interactions leading 
to the formation of p53 homotetramers as well as p53 hetero-
oligomers. In addition the C-terminus of p53 plays a major 
regulatory role for the specific DNA binding activity of the 
core domain (for review see [13]). A motif within the C-ter-
minal 30 amino acids negatively controls p53 function as de-
letion of these amino acids constitutively activates p53 for 
DNA binding [19] and abolishes the DNA reannealing activ-
ity of p53 [25]. The C-terminus is also the target for post-
translational modifications such as phosphorylation by differ-
ent protein kinases namely p34cdc2 [37], protein kinase C [38] 
and protein kinase CK2 [39]. Phosphorylation of p53 by CK2 
on its penultimate amino acid has been shown to activate 
sequence-specific DNA binding of p53 at least in vitro [39]. 
in lane 1) resulted in a shift in mobility and the band was 
supershifted in the presence of monoclonal antibody PAb421 
(lane 7). Addition of the ß-subunit of CK2 abolished DNA 
binding of p53 (lane 11). However, addition of PAb421 to p53 
and the ß-subunit resulted in a supershift (lane 8) as in the 
absence of the ß-subunit (lane 7) indicating that PAb421 has a 
higher affinity for p53 than the ß-subunit of CK2. Lane 3 
shows the control cell extract with DNA and ß-subunit and 
lane 4 control cell extract with DNA, ß-subunit and PAb421. 
The unspecific DNA binding of the cell extract is shown in 
lanes 5 and 6 (with and without PAb421, respectively). Con-
trol experiments showed that the ß-subunit of CK2 did not 
bind to the p53 oligonucleotide neither in the presence (lane 
10) nor in the absence of monoclonal antibody PAb421(lane 
9). Thus, we conclude that the interaction of the regulatory ß-
subunit of CK2 with p53 reduces the DNA binding activity of 
p53 considerably. 
In order to analyze the DNA binding of p53 in the presence 
of the ß-subunit of CK2 in more detail we repeated the experi-
ment described above but in the presence of increasing 
amounts of the ß-subunit of CK2. As shown in Fig. 5 lane 
6, p53 binds to DNA. However, binding is reduced in the 
presence of a molecular ratio of p53/ß-subunit of 8:1, 6:1, 
4:1 and 2:1 of the ß-subunit of CK2 (lanes 5-2). Lane 1 
Fig. 3. DNA binding of p53 in the presence of the ot-subunit of 
CK2. The 32P-labeled oligonucleotide containing the p53 consensus 
sequence was incubated under DNA binding conditions with cell ex-
tracts (p53 or control, respectively) in the absence (lanes 1, 3, 4, 7, 
8) or presence (lanes 2, 5, 6, 9, 10) of α-subunit of CK2. In addi-
tion lanes 4, 6, 8 and 10 contain monoclonal antibody PAb421. 
After an incubation time of 30 min the probes were analyzed on a 
4% polyacrylamide gel, followed by autoradiography of the gel. 
Lane 1: DNA. Lane 2: DNA with rx-subunit. Lane 3: Control cell 
extract with DNA. Lane 4: Control cell extract with DNA and 
PAb421. Lane 5: Control cell extract with DNA and a-subunit. 
Lane 6: Control cell extract with DNA, α-subunit and PAb421. 
Lane 7: p53 cell extract with DNA. Lane 8: p53 cell extract with 
DNA and PAb421. Lane 9: p53 cell extract with DNA and a-sub-
unit. Lane 10: p53 cell extract with DNA, α-subunit and PAb421. 
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It has been shown that binding of monoclonal antibody 
PAb421 to p53 influences phosphorylation of p53 by CK2. 
Phosphorylation of p53 by CK2 seems to be important for 
the growth suppressor function of p53 because it was shown 
that an alanine-389 mutant of mouse p53 is no longer able to 
suppress cell growth [40] while the DNA binding function is 
not inhibited for this mutated p53 [41]. An alanine-392 mu-
tant of human p53 has no transforming capability [42]. More-
over, a serine-392 to alanine exchange has no effect on the 
transactivation activity of p53 whereas the transrepression 
activity of p53 on the c-fos promotor is inhibited [43]. In 
addition to the phosphorylation of p53 by CK2 it was shown 
that p53 binds to the regulatory ß-subunit of protein kinase 
CK2 by C-terminal sequences spanning amino acids 287-340 
[21]. In the present paper we described that in addition to the 
phosphorylation of p53 by protein kinase CK2 also binding of 
the regulatory ß-subunit to p53 influenced the DNA binding 
activity of p53. DNA binding of p53 is reduced by the ß-
subunit of CK2 whereas the a-subunit of CK2 had no influ-
ence. The CK2 holoenzyme seems to activate the DNA bind-
Fig. 5. DNA binding of p53 in the presence of increasing amounts 
of the ß-subunit of CK2. The 32P-endlabeled oligonucleotide con-
taining the p53 consensus sequence was incubated under DNA bind-
ing conditions with p53 in the absence (lanes 1 and 6) or presence 
of increasing amounts of the ß-subunit of CK2 (lanes 5-2). After in-
cubation for 30 min. samples were analyzed on a 4% polyacryl-
amide gel followed by autoradiography. Lane 1: DNA. Lane 2: p53 
cell extract and ß-subunit molar ratio 2:1 and DNA. Lane 3: p53 
cell extract and ß-subunit molar ratio 4:1 and DNA. Lane 4: p53 
cell extract and ß-subunit molar ratio 6:1 and DNA. Lane 5: p53 
cell extract and ß-subunit molar ratio 8:1 and DNA. Lane 6: p53 
cell extract with DNA. 
Fig. 4. DNA binding of p53 in the presence of the ß-subunit of 
CK2. The 32P-endlabeled oligonucleotide containing the p53 consen-
sus sequence was incubated under DNA binding conditions with 
cell extracts (p53 or control, respectively) in the absence (lanes 1, 2, 
5, 6, 7) or presence (lanes 3, 4, 8, 9, 10, 11) of ß-subunit of CK2. 
In addition lanes 4, 5, 7, 8 and 10 contain monoclonal antibody 
PAb421. After an incubation time of 30 min the probes were ana-
lyzed on a 4% polyacrylamide gel followed by autoradiography of 
the gel. Lane 1: DNA. Lane 2: p53 cell extract with DNA. Lane 3: 
Control cell extract with DNA and ß-subunit. Lane 4: Control cell 
extract with DNA, ß-subunit and PAb421. Lane 5: Control cell ex-
tract with DNA and PAb421. Lane 6: Control cell extract with 
DNA. Lane 7: p53 cell extract with DNA and PAb421. Lane 8: 
p53 cell extract with DNA, ß-subunit and PAb421. Lane 9: DNA 
with ß-subunit. Lane 10: DNA with ß-subunit and PAb421. Lane 
11: p53 cell extract with DNA and ß-subunit. 
ing properties of p53 similar to monoclonal antibody PAb421 
[39] and similar to a C-terminal peptide of p53 spanning ami-
no acids 264-393 (data not shown). 
Wild-type p53 promotes the rapid renaturation of comple-
mentary RNA and DNA strands [44]. Furthermore, the C-
terminus of p53 recognizes DNA with mismatches and more-
over it has the capacity to form stable complexes with dam-
aged DNA [24]. Complex formation of p53 with the ß-subunit 
of CK2 as well as binding of monoclonal antibody PAb421 to 
p53 results in loss of the p53 annealing activity [45]. 
There is some controversy about the subcellular localization 
of CK2. Depending on the cell lines used for the analysis, the 
individual subunits of CK2 are found in the cytoplasm, nu-
cleus or in the nucleoli [28,46], intracellular localizations 
where also p53 has been found [47,48]. Moreover, in addition 
to the holoenzyme of CK2 free oc- and free ß-subunits are 
found within the same cell [49]. In the present paper we dem-
onstrated an individual role of the free ß-subunit compared to 
the ß-subunit in a CK2 holoenzyme. The ß-subunit of CK2 
reduced DNA binding activity of p53 whereas the holoenzyme 
led to a supershift of p53/DNA complexes. The α-subunit had 
no influence on the DNA binding activity of p53. 
The fibroblast growth factor-2 [50] and the C-terminus of 
p53 [26] also bind to the ß-subunit of CK2 which lead to an 
increase in the enzymatic activity. In addition to this direct 
effect of p53 on the CK2 activity there seems to be an indirect 
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effect. U p o n D N A damage the intracellular level of p53 in-
creases [51]. This elevated level of p53 leads to a transcrip-
tional activation of the p 2 1 W A F l gene expression [52]. The 
p21 W A F 1 protein was shown to inhibit the cyclin dependent 
kinases [53] and in addition also protein kinase CK2 at least 
in vitro [30]. 
Several years ago it was shown that purified protein kinase 
CK2 associates with double stranded D N A in vitro [54]. This 
D N A binding is mediated by the α-subunit of CK2. Recently, 
it was shown that the oc-subunit binds to the promoter of the 
CK2 ß-subunit gene thereby regulating its transcription [55]. 
However, in the present report we demonstrated that the a-
subunit neither bound to the p53-specific oligonucleotide nor 
influenced the binding of p53 to D N A . 
Thus, from all of these data it is evident that the ß-subunit 
is the target for the regulation of the activity of the CK2 
holoenzyme. However, the free a- and free ß-subunits also 
have individual roles in regulation of various cellular activ-
ities. 
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